Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 7/20 | 0.68 |
| ▸ | MAX | P61244 | 6/20 | 0.68 |
| ▸ | EP300 | Q09472 | 3/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12068659 | 0.99 | MYC (0.69) | MYCMAXEP300HIF1AAR | |
| SCHEMBL12068700 | 0.99 | MYC (0.69) | MYCMAXEP300HIF1AAR | |
| SCHEMBL12068665 | 0.98 | MYC (0.71) | MYCMAXEP300HIF1AAR | |
| SCHEMBL12068655 | 0.97 | EP300 (0.73) | MYCMAXEP300HIF1AAR | |
| SCHEMBL12068719 | 0.97 | MYC (0.69) | MYCMAXEP300HIF1AAR | |
| SCHEMBL12068691 | 0.92 | EP300 (0.81) | MYCMAXEP300HIF1AAR | |
| SCHEMBL12068654 | 0.91 | EP300 (0.62) | MYCMAXEP300HIF1AAR | |
| SCHEMBL12068656 | 0.91 | EP300 (0.79) | MYCMAXEP300HIF1AAR | |
| SCHEMBL12068723 | 0.91 | EP300 (0.62) | MYCMAXEP300HIF1AAR | |
| SCHEMBL12068664 | 0.91 | EP300 (0.79) | MYCMAXEP300HIF1AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856206-B2 | Oligo-benzamide compounds and their use | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160130217-A1 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160130217-A1 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-12 | — | — | US | disclosed |
| US-20130231385-A1 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231385-A1 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2011150360-A1 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130217-A1 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE | AR, OGFR, BRDT | MYC 23/4885MAX 4203/4885EP300 509/4885 |
| US-20130231385-A1 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE | AR, OGFR, BRDT | MYC 23/4885MAX 4203/4885EP300 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.